Swiss franc

EQS-News: HSO Fund reports 11.8% return on investment in financial year 2020

Thursday, April 8, 2021 - 7:00am

Zurich, 8 April 2021 - The Helvetica Swiss Opportunity Fund (HSO Fund) has built an excellent specialized real estate portfolio with a market value of CHF 110.3 million in its first financial year 2020.

Key Points: 
  • Zurich, 8 April 2021 - The Helvetica Swiss Opportunity Fund (HSO Fund) has built an excellent specialized real estate portfolio with a market value of CHF 110.3 million in its first financial year 2020.
  • The Helvetica Swiss Opportunity Fund (HSO Fund) focuses on special purpose properties that have a good risk/return ratio.
  • In the financial year 2020, the rental income of the portfolio amounted to CHF 5.7 million.
  • The HSO Fund has a substantial investment pipeline and the fund management company Helvetica Property Investors AG is convinced of the long-term attractiveness of the Swiss real estate market.

EQS-News: HSL Fund built up attractive residential property portfolio with more than 500 apartments in 2020 financial year

Wednesday, April 7, 2021 - 7:00am

Zurich, 7 April 2021 - The Helvetica Swiss Living Fund (HSL Fund) built up an attractive portfolio of residential properties with 517 apartments and a market value of CHF 221.5 million (1 January 2021) in the financial year 2020.

Key Points: 
  • Zurich, 7 April 2021 - The Helvetica Swiss Living Fund (HSL Fund) built up an attractive portfolio of residential properties with 517 apartments and a market value of CHF 221.5 million (1 January 2021) in the financial year 2020.
  • of CHF 8.9 million per 31.12.2020; per 01.01.2021 at CHF 9.7 million
    The HSL Fund was able to build up an attractive residential property portfolio during its first extended fiscal year 2020 (6 November 2019 to 31 December 2020) - despite the COVID-19 pandemic.
  • The market value of the portfolio amounted to CHF 204.3 million as of 31 December 2020.
  • In addition, the listing of the HSL Fund on the SIX Swiss Exchange by the end of 2022 is under consideration.

Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results

Wednesday, March 31, 2021 - 1:30pm

Hamilton, Bermuda, March 31, 2021 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today provided a business update and announced second half and full year 2020 financial results.

Key Points: 
  • Hamilton, Bermuda, March 31, 2021 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today provided a business update and announced second half and full year 2020 financial results.
  • Total operating expenses for the second half of 2020 were CHF 2.9 million compared to CHF 3.2 million for the second half of 2019.
  • General and administrative expenses for the second half of 2020 were CHF 1.1 million compared to CHF 1.1 million for the second half of 2019.
  • Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders.

Nespresso invests CHF 117 million in the expansion of its Avenches production center to meet growing consumer demand

Thursday, March 18, 2021 - 7:30am

LAUSANNE, Switzerland, March 18, 2021 /PRNewswire/ -- Nespresso invests CHF 117 million to expand its Avenches production center in Switzerland to meet increasing consumer demand for its high-quality premium coffees and support international development, creating 50 new jobs by the end of 2022.

Key Points: 
  • LAUSANNE, Switzerland, March 18, 2021 /PRNewswire/ -- Nespresso invests CHF 117 million to expand its Avenches production center in Switzerland to meet increasing consumer demand for its high-quality premium coffees and support international development, creating 50 new jobs by the end of 2022.
  • The Avenches production center acts as Nespresso's global distribution center, shipping capsules to over 80 countries around the world, and is dedicated to the production of Nespresso Original and Professional coffees as well as Starbucks by Nespresso.
  • Over the past eight months we have announced a total of CHF 270 million investment in both our Romont and Avenches production centers.
  • Nespresso opened its production center in Avenches in 2008, with an initial investment of CHF 300 million, later complemented with CHF 200 million invested in its infrastructure and operations in Avenches, a total of CHF 500 million since 2009.

Nespresso invests CHF 117 million in the expansion of its Avenches production center to meet growing consumer demand

Thursday, March 18, 2021 - 7:30am

LAUSANNE, Switzerland, March 18, 2021 /PRNewswire/ -- Nespresso invests CHF 117 million to expand its Avenches production center in Switzerland to meet increasing consumer demand for its high-quality premium coffees and support international development, creating 50 new jobs by the end of 2022.

Key Points: 
  • LAUSANNE, Switzerland, March 18, 2021 /PRNewswire/ -- Nespresso invests CHF 117 million to expand its Avenches production center in Switzerland to meet increasing consumer demand for its high-quality premium coffees and support international development, creating 50 new jobs by the end of 2022.
  • The Avenches production center acts as Nespresso's global distribution center, shipping capsules to over 80 countries around the world, and is dedicated to the production of Nespresso Original and Professional coffees as well as Starbucks by Nespresso.
  • Over the past eight months we have announced a total of CHF 270 million investment in both our Romont and Avenches production centers.
  • Nespressoopened its production center in Avenches in 2008, with an initial investment of CHF 300 million, later complemented with CHF 200 million invested in its infrastructure and operations in Avenches, a total of CHF 500 million since 2009.

EQS-News: u-blox AG: u-blox reports full year 2020 financial results

Friday, March 12, 2021 - 7:00am

For the full-year 2020, u-blox generated revenues of CHF 333.5 million, EBIT (adjusted) of CHF 18.0 million and EBITDA (adjusted) of CHF 42.2 million.

Key Points: 
  • For the full-year 2020, u-blox generated revenues of CHF 333.5 million, EBIT (adjusted) of CHF 18.0 million and EBITDA (adjusted) of CHF 42.2 million.
  • AMEC and EMEA were especially affected by prolonged automotive and business shutdowns and companies adopting a delayed approach through much of 2020.
  • In APAC, full-year 2020 revenues amounted to CHF 137.7 million compared to CHF 145.6 million in 2019 (-5.4%).
  • Share based payment expenses recognized according to IFRS in 2020 were CHF 4.8 million compared to CHF 5.3 million in 2019.

Addex Reports Full Year 2020 Financial Results and Provides Corporate Update

Thursday, March 11, 2021 - 6:00am

The net loss for 2020 was CHF 12.9 million compared to CHF 14.8 million for 2019 primarily due to the decrease in R&D costs.

Key Points: 
  • The net loss for 2020 was CHF 12.9 million compared to CHF 14.8 million for 2019 primarily due to the decrease in R&D costs.
  • Cash and cash equivalentsamounted to CHF 18.7 million at December 31, 2020 compared to CHF 31.5 million at December 31, 2019.
  • 2020 Condensed Consolidated Interim Financial Statements:
    A conference call will be held today,March 11, 2021, at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST)to review the financial results.
  • Addex is listed on the SIX Swiss Exchange and the NASDAQ Capital Market and trades under the ticker symbol "ADXN".

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1

Wednesday, March 3, 2021 - 6:00am

EBITDA increased to CHF 575.8 million compared to CHF 485.0 million in the previous year, an increase of 18.7%, or 29.4% at CER.

Key Points: 
  • EBITDA increased to CHF 575.8 million compared to CHF 485.0 million in the previous year, an increase of 18.7%, or 29.4% at CER.
  • Marketing and distribution expenses amounted to CHF 403.8 million compared to CHF 435.7 million in the previous year, down 7.3%.
  • Investments in research and development amounted to CHF 250.0 million compared to CHF 212.0 million in the previous year.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

EQS-News: Report on CPH: FY2020 earnings update

Thursday, February 25, 2021 - 7:01am

This report is published by Research Dynamics, an independent research boutique

Key Points: 
  • This report is published by Research Dynamics, an independent research boutique
    CPH reported a sound operating performance for FY2020, which otherwise was marked by the Covid-19 induced economic slump.
  • Group net sales in FY2020 declined by 15.1% YoY to CHF 445.2mn (-10.7% excluding currency impact).
  • Lower energy and raw material costs (in the Paper and Packaging Divisions) also helped in mitigating the decline.
  • Group EBIT declined by 56% YoY to CHF 24.7mn (FY2019: CHF 56.6mn), the corresponding margin compressing to 5.5% (10.8%).

Basilea reports preliminary 2020 revenue and portfolio progress

Monday, January 11, 2021 - 6:15am

Basilea also reported preliminary CHF 167 million cash and financial investments at year-end 2020.

Key Points: 
  • Basilea also reported preliminary CHF 167 million cash and financial investments at year-end 2020.
  • Basilea had guided for total revenue of CHF 128-138 million with total revenue contributions from Cresemba and Zevtera of CHF 110-120 million and a year-end cash position of CHF 150 million.
  • Both Cresemba and Zevtera have been approved and launched in new markets throughout 2020, which has triggered multiple milestone payments to Basilea.
  • The final audited revenue for 2020 and the cash position as of year-end 2020 may differ from the preliminary reported numbers.